Javelin shares slide as merger deal gets dicey; SEC charges ex-R&D chief at Sequenom with lying;

 @FierceBiotech: Report: Pharma cuts 6,943 jobs in May. Article | Follow @FierceBiotech

 @JohnCFierce: Two months ahead of schedule, FDA approves D-mab. Article | Follow @JohnCFierce

> Shares of Javelin Pharmaceuticals slid 15 percent this morning after Hospira extended its tender offer for the second time. Javelin filed a lawsuit to compel Hospira to complete an agreed acquisition, but Hospira is now leery of the deal after UK officials forced the recall of the pain med Dyloject. Story

> The former head of R&D at Sequenom, Elizabeth Dragon, has been charged by the SEC with lying to analysts about the accuracy of the company's screening test for Down syndrome. Report

> Exelixis is raising $160 million in order to repay a loan from GlaxoSmithKline, a former partner. Story

> Astellas Pharma is close to obtaining the 90 percent of OSI shares needed to complete its acquisition. Report

> Switzerland's PregLem says that its new drug for uterine fibroids met its goals in a late-stage trial. The company says it will file for European approval later this year. Report

> Owings Mill, MD-based Nora Therapeutics has raised close to $3 million, part of a planned $25 million round, according to regulatory filings. Burrill Life Sciences, Prospect Venture Partners and Vivo Ventures contributed to a $25 million round in 2008. Story

And Finally... The pheromone that attracts female mice to the odor of a particular male has been identified. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.